Does using proscar during a cycle hinder your gains? I read somewhere at MC that you shouldn't use Proscar if your a bodybuilder because it hurts your gains. But I have also read many places of guys using proscar during their cycle. Can someone with experience clear this up for me. Thanks.
Proscar use on cycle!!
- Thread starter gettnbig2
- Start date
DecaDent*
New member
It doesn't hinder gains IMO. It's a type 2, 5-alpha-reductase inhibitor that prevents T from turning into DHT. DHT is responsible for MPbaldness+prostate enlargement so Proscar minimizes the effects by reducing T to DHT conversion in those areas. They come in 5mg tabs and 1/4 tab a day with some saw palmetto is what I take.
superchicken
New member
http://www.testosterones.com/dht.htm
i think it does, not a ton, but dht is good for us other than the bad sides. i have a better link than this, ill try and find it.
i think it does, not a ton, but dht is good for us other than the bad sides. i have a better link than this, ill try and find it.
superchicken
New member
nevermind that was the good link 
Good link SC. But what the hell do I do. it says that it may hinder gains and it may be bad to block test from converting to DHT. So does that mean that if I want gains I have to let my hair fall out? Is there anything else I can take or does anyone have experiance using Proscar during a cycle? Does it hurt your gains? If it only hurts it a little it better than losing you hair but if it kills them then I guess its, good bye hair!
DecaDent*
New member
Here's a recent review of the drug for you.
Clin Pharmacokinet 1996 Jan;30(1):16-27 (ISSN: 0312-5963)
Steiner JF
Family Practice Residency Program, University of Wyoming, Casper 82071, USA.
Finasteride is a potent 5 alpha-reductase inhibitor that has shown limited success in men treated for benign prostatic hyperplasia (success is defined as a decrease in the symptoms associated with urinary tract obstruction, and as increases in the urinary flow rate). 5 alpha-reductase is necessary for the prostatic conversion of testosterone to dihydrotesterone (DHT), the specific steroid that stimulates prostate transitional zone growth. Finasteride reduces the size of the prostate gland by 20%, but this does not correlate well with improvement in symptoms. Finasteride is well absorbed after oral administration and, while the rate of absorption may be slowed postprandially, the presence of food has no effect on the total bioavailability. Finasteride is widely distributed, but since its pharmacological effects are very specific to inhibition of 5 alpha-reductase, and since only the prostate gland, the scalp, and the genital skin contain high concentrations of this enzyme, few adverse reactions will be seen in other organ systems. Finasteride undergoes extensive hepatic metabolism to essentially inactive metabolites, which are eliminated through the bile and urine. The terminal elimination half-life (t1/2z) is 4.7 to 7.1 hours; but despite this, slow accumulation occurs with multiple doses. Values of t1/2z are higher in elderly men, but no dosage adjustments are necessary. Likewise, no dosage adjustments are necessary for patients with renal dysfunction, since the metabolites which accumulate are relatively inactive and well tolerated, and because greater faecal excretion of the metabolites occurs in these patients. The effect of hepatic dysfunction on the metabolism of finasteride is unknown. Therapeutic doses of finasteride produce a rapid and pronounced effect in reducing both plasma and prostate tissue levels of DHT. Doses below 0.5 mg/day do not produce much suppression of DHT levels, and doses above 5 mg/day have little additional benefit. A single dose of finasteride suppresses serum DHT levels for up to 4 days, longer than would be expected from the serum terminal elimination half-life (t1/2z) of the drug: this is probably due to the high affinity that finasteride has for the 5 alpha-reductase enzyme. Serum testosterone levels increase in patients receiving finasteride, but are not normally outside the upper limits of the normal range. Serum prostate-specific antigen (PSA) levels decrease with finasteride administration; the baseline for investigation of prostate cancer with elevated PSA levels should be one-half of the normal range. In responders to finasteride, the prostate gland shrinks in volume by about 20%, urinary flow rate improves by approximately 3 ml/s, and symptoms are relieved. The response to finasteride appears to be maximal at doses of 5 mg/day. For most men receiving finasteride, these effects will persist for at least the 5 years that long term studies have been conducted. Serum DHT levels increase again when finasteride therapy is discontinued, probably resulting in the return of the hyperplasia, decreased urine flow and obstructive symptoms. Finasteride is well tolerated, with loss of libido and sexual potency being the most commonly reported adverse reactions. No drug interactions with finasteride have been reported
Clin Pharmacokinet 1996 Jan;30(1):16-27 (ISSN: 0312-5963)
Steiner JF
Family Practice Residency Program, University of Wyoming, Casper 82071, USA.
Finasteride is a potent 5 alpha-reductase inhibitor that has shown limited success in men treated for benign prostatic hyperplasia (success is defined as a decrease in the symptoms associated with urinary tract obstruction, and as increases in the urinary flow rate). 5 alpha-reductase is necessary for the prostatic conversion of testosterone to dihydrotesterone (DHT), the specific steroid that stimulates prostate transitional zone growth. Finasteride reduces the size of the prostate gland by 20%, but this does not correlate well with improvement in symptoms. Finasteride is well absorbed after oral administration and, while the rate of absorption may be slowed postprandially, the presence of food has no effect on the total bioavailability. Finasteride is widely distributed, but since its pharmacological effects are very specific to inhibition of 5 alpha-reductase, and since only the prostate gland, the scalp, and the genital skin contain high concentrations of this enzyme, few adverse reactions will be seen in other organ systems. Finasteride undergoes extensive hepatic metabolism to essentially inactive metabolites, which are eliminated through the bile and urine. The terminal elimination half-life (t1/2z) is 4.7 to 7.1 hours; but despite this, slow accumulation occurs with multiple doses. Values of t1/2z are higher in elderly men, but no dosage adjustments are necessary. Likewise, no dosage adjustments are necessary for patients with renal dysfunction, since the metabolites which accumulate are relatively inactive and well tolerated, and because greater faecal excretion of the metabolites occurs in these patients. The effect of hepatic dysfunction on the metabolism of finasteride is unknown. Therapeutic doses of finasteride produce a rapid and pronounced effect in reducing both plasma and prostate tissue levels of DHT. Doses below 0.5 mg/day do not produce much suppression of DHT levels, and doses above 5 mg/day have little additional benefit. A single dose of finasteride suppresses serum DHT levels for up to 4 days, longer than would be expected from the serum terminal elimination half-life (t1/2z) of the drug: this is probably due to the high affinity that finasteride has for the 5 alpha-reductase enzyme. Serum testosterone levels increase in patients receiving finasteride, but are not normally outside the upper limits of the normal range. Serum prostate-specific antigen (PSA) levels decrease with finasteride administration; the baseline for investigation of prostate cancer with elevated PSA levels should be one-half of the normal range. In responders to finasteride, the prostate gland shrinks in volume by about 20%, urinary flow rate improves by approximately 3 ml/s, and symptoms are relieved. The response to finasteride appears to be maximal at doses of 5 mg/day. For most men receiving finasteride, these effects will persist for at least the 5 years that long term studies have been conducted. Serum DHT levels increase again when finasteride therapy is discontinued, probably resulting in the return of the hyperplasia, decreased urine flow and obstructive symptoms. Finasteride is well tolerated, with loss of libido and sexual potency being the most commonly reported adverse reactions. No drug interactions with finasteride have been reported
superchicken
New member
good info decadent.
another way if all your concerned about is hair, is get topical dht blockers.
another way if all your concerned about is hair, is get topical dht blockers.
superchicken
New member
nizoral(just use it cause its cheap shampoo, not the most effective for hair loss though), topical spironolactone(very good).
minoxodil and rogain are supposed to help also.
minoxodil and rogain are supposed to help also.
superchicken
New member
im about to start taking prob about .5-.75mg finast ed while on cycle. im not trying to eliminate it, i havent had any hair probs, im just thinking about the prostate, and im sure eventually my hair may thin
SAMSONN
New member
minoxidil.com is a good place to get spirono and
www.dru-online.com is a cheap place for finasteride
www.dru-online.com is a cheap place for finasteride
Similar threads
